Aleksandra Siegmund

Aleksandra Siegmund

Auto-generated profile, based on publicly available information

Aleksandra Siegmund

Medical University of Silesia in Katowice, Katowice, Silesia, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JGJulia Gatniejewska
Julia Gatniejewska
MSMartyna Sienicka
Martyna Sienicka
PPPaulina Prudzic
Paulina Prudzic
WWWeronika Winiarska
Weronika Winiarska
WBWiktoria Bełcikowska-Skowron
Wiktoria Bełcikowska-Skowron
EPEmilia Przybyszewska
Emilia Przybyszewska
Introduction: Irritable bowel syndrome is characterized by symptoms such as abdominal pain associated with defecation and changes in stool frequency and/or consistency. In recent years, the low-FODMAP diet has become one of the most commonly used dietary interventions. Aim of the study: The aim of this study was to assess the effectiveness of the low-FODMAP diet and to identify its limitations and consistency with current guidelines. Methods: A narrative review of the literature was conducted, including 31 publications from 2012–2026, such as original research articles, randomized controlled trials, systematic reviews, meta-analyses, and current clinical guidelines on the diagnosis and treatment of IBS. PubMed and Google Scholar databases were searched using predefined inclusion and exclusion criteria. Main findings: The results of the analyzed studies indicate that the low-FODMAP diet may reduce IBS symptoms such as bloating, abdominal pain, and intestinal discomfort. However, no clear superiority over other dietary strategies has been demonstrated. Clinical response varies and may depend on the patient’s gut microbiota. Data on the use of the low-FODMAP diet in the pediatric population and other special clinical groups are limited and do not allow definitive conclusions to be drawn. Conclusions: The low-FODMAP diet is an effective therapeutic option in selected patients with IBS; however, it should be implemented in stages, including elimination, reintroduction, and personalization phases. Supervision by a dietitian and individual adjustment of recommendations to the patient’s needs are recommended. Further studies are needed to assess the long-term effects of the diet and predictors of clinical response.

31 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AFAgnieszka Filarecka
Agnieszka Filarecka
PPPiotr Przybyszewski
Piotr Przybyszewski
EPEmilia Przybyszewska
Emilia Przybyszewska
JGJulia Gatniejewska
Julia Gatniejewska
MSMartyna Sienicka
Martyna Sienicka
MCMarzena Chrapczyńska
Marzena Chrapczyńska
Introduction: Bronchial asthma remains a significant clinical problem despite advances in pharmacological treatment. Approximately 5–10% of asthma patients suffer from a severe, uncontrolled form of the disease associated with frequent exacerbations, impaired lung function, reduced quality of life, and increased hospitalization rates. The introduction of biologic therapies targeting Th2-dependent inflammatory pathways has significantly improved treatment outcomes in this group of patients. Aim of the Study: The aim of this study was to analyze and compare the efficacy and safety of biologic therapies used in the treatment of severe asthma, with particular emphasis on tezepelumab, mepolizumab, benralizumab, and dupilumab, based on clinical trials and real-world studies. Materials and Methods: A literature review was conducted using the PubMed database. Original clinical trials, prospective studies, and real-world observational studies published between 2020 and 2026 were included in the analysis. The effects of biologic therapies on asthma exacerbation reduction, improvement in lung function, reduction in oral corticosteroid use, achievement of clinical remission, and long-term treatment safety were evaluated. Results: All analyzed biologic therapies demonstrated significant clinical efficacy in the treatment of severe asthma. Tezepelumab led to a substantial reduction in the number of exacerbations, improvement in pulmonary function parameters, and reduction in oral corticosteroid use regardless of eosinophil levels. Mepolizumab and benralizumab showed comparable efficacy, particularly in patients with eosinophilic asthma. Dupilumab demonstrated high efficacy in patients with type 2 inflammation, especially regarding improvement in lung function. Real-world studies confirmed the effectiveness and favorable safety profile of biologic therapies observed in randomized clinical trials. Conclusions: Biologic therapies constitute an effective and safe treatment option for severe asthma and significantly improve disease control and patients’ quality of life. The strongest clinical evidence concerns tezepelumab, mepolizumab, benralizumab, and dupilumab; however, treatment efficacy may depend on the disease phenotype and inflammatory biomarkers. Further studies are needed to optimize the personalization of biologic therapies and to standardize remission criteria in severe asthma.

18 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
WBWiktoria Bełcikowska-Skowron
Wiktoria Bełcikowska-Skowron
ASAleksandra Siegmund
Aleksandra Siegmund
MCMarzena Chrapczyńska
Marzena Chrapczyńska
AFAgnieszka Filarecka
Agnieszka Filarecka
PPPiotr Przybyszewski
Piotr Przybyszewski
WWWeronika Winiarska
Weronika Winiarska
Childhood overweight and obesity remain major global public health challenges associated with increased cardiometabolic risk, psychosocial complications, and persistence into adulthood. Lifestyle interventions are considered the first-line strategy for obesity prevention and treatment in pediatric populations. The aim of this systematic review was to evaluate the effectiveness of lifestyle interventions in preventing and treating overweight and obesity among children and adolescents aged 0–18 years. A systematic literature review of randomized controlled trials published between January 2016 and March 2026 was conducted using PubMed and Google Scholar databases. Studies involving dietary, physical activity, behavioral, family-based, school-based, or technology-assisted interventions were included. Following screening and eligibility assessment, 39 randomized controlled trials were included in the narrative synthesis. Most interventions combined nutritional education, physical activity, behavioral strategies, and family or school involvement. Family-based and intensive multicomponent interventions demonstrated the most consistent improvements in body mass index (BMI) and health-related behaviors. School-based interventions generally improved lifestyle behaviors; however, their effects on anthropometric outcomes were less consistent. Technology-assisted interventions, including exergaming and wearable devices, produced mixed results. Several studies also reported improvements in metabolic parameters, physical activity, and quality of life despite modest BMI reductions. Overall, lifestyle interventions may support the prevention and treatment of childhood obesity, although their effects on BMI are generally moderate. The most effective interventions appear to be intensive, family-centered, and multicomponent. Future research should focus on long-term follow-up, implementation feasibility, and sustainable intervention strategies.

16 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MSMartyna Sienicka
Martyna Sienicka
WWWeronika Winiarska
Weronika Winiarska
WBWiktoria Bełcikowska-Skowron
Wiktoria Bełcikowska-Skowron
ASAleksandra Siegmund
Aleksandra Siegmund
MCMarzena Chrapczyńska
Marzena Chrapczyńska
PPPaulina Prudzic
Paulina Prudzic
Polycystic ovary syndrome (PCOS) is a multifaceted endocrine and metabolic condition affecting women of reproductive age. While historically conceptualized as a reproductive disorder, current evidence indicates that PCOS extends beyond ovulatory dysfunction and hyperandrogenism to include significant metabolic, psychological, and quality of life consequences. Insulin resistance represents a core pathophysiological feature of the syndrome, contributing to hyperinsulinemia, exacerbation of androgen excess, menstrual irregularities, and long term metabolic risk. This narrative review synthesizes current literature on the mechanisms and clinical implications of insulin resistance in PCOS, drawing from peer reviewed studies, systematic reviews, meta analyses, and international guidelines. Evidence shows that insulin resistance is prevalent across PCOS phenotypes, including in women without obesity, and is strongly associated with impaired glucose metabolism, dyslipidemia, metabolic syndrome, and increased cardiometabolic vulnerability. Psychological burden is also substantial, with many women reporting depressive and anxiety symptoms, body image concerns, fertility related distress, and reduced overall wellbeing. Interactions between metabolic dysfunction, emotional health, and lifestyle factors further contribute to diminished health related quality of life. Collectively, these findings highlight the need for early metabolic assessment, individualized therapeutic strategies, and interdisciplinary care models addressing both physiological and psychosocial dimensions of PCOS. A comprehensive approach to insulin resistance may improve reproductive, metabolic, and psychological outcomes and support more patient centered long term management.

18 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
PPPiotr Przybyszewski
Piotr Przybyszewski
EPEmilia Przybyszewska
Emilia Przybyszewska
AFAgnieszka Filarecka
Agnieszka Filarecka
WWWeronika Winiarska
Weronika Winiarska
ASAleksandra Siegmund
Aleksandra Siegmund
WBWiktoria Bełcikowska-Skowron
Wiktoria Bełcikowska-Skowron
Background: Physical exercise is an important non-pharmacological strategy for reducing blood pressure (BP) and preventing cardiovascular disease. Methods: This narrative review analyzed evidence from randomized controlled trials, systematic reviews, and meta-analyses on the effects of different exercise modalities on BP reduction. Results: Aerobic, resistance, isometric, combined training, and high-intensity interval training (HIIT) all demonstrated significant antihypertensive effects. Aerobic exercise improved vascular function, resistance training enhanced functional capacity, and isometric exercise showed particularly strong reductions in systolic BP. Greater BP reductions were observed in hypertensive and resistant hypertensive populations. Conclusion: Regular physical exercise effectively reduces BP and should be considered a key component of hypertension prevention and management. Individualized and sustained exercise interventions may provide substantial cardiovascular benefits.

25 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
PPPaulina Prudzic
Paulina Prudzic
WWWeronika Winiarska
Weronika Winiarska
WBWiktoria Bełcikowska-Skowron
Wiktoria Bełcikowska-Skowron
ASAleksandra Siegmund
Aleksandra Siegmund
MCMarzena Chrapczyńska
Marzena Chrapczyńska
JGJulia Gatniejewska
Julia Gatniejewska
As Europe’s population ages, managing polypharmacy has evolved from an individual clinical concern into a major public health priority [3, 4]. Broadly driven by multi-organ chronic diseases and uncoordinated specialist care, the accumulation of multiple drug prescriptions generates heavy clinical and economic costs [5, 6]. This narrative review maps the neurological risks linked to polypharmacy and evaluates the structural healthcare factors that shape prescribing habits across European nations [1, 12]. Gathering data published between 2010 and 2024, we synthesized evidence regarding regional prevalence, cumulative anticholinergic burden, and system-level weaknesses [4, 14]. Current statistics reveal that 40–50% of older Europeans aged ≥ 65 years face polypharmacy, though rates differ widely between countries [4, 24]. The central nervous system bears a disproportionate share of drug-induced harm; common outcomes include accelerated cognitive decline, acute delirium, motor instabilities, and the worsening of pre-existing psychiatric or epileptic conditions [13, 14, 19]. Much of this damage stems directly from an unmonitored anticholinergic burden, which tracks closely with elevated dementia rates and mortality [15, 16]. At the institutional level, fragmented communication between physicians, poor access to comprehensive geriatric assessments, and the absence of routine medication reviews act as primary drivers of unsafe prescribing [2, 26]. Mitigating these risks requires integrating targeted organizational shifts—such as mandatory deprescribing protocols and clinical pharmacist oversight—with digital infrastructure, including artificial intelligence platforms and clinical decision-support software [7, 31, 33, 34].